Gummies For Good Health: Enhancing TB Treatment with Isoniazid Oral Gummies

Isoniazid, a key drug in the treatment and prevention of tuberculosis (TB), is traditionally administered in tablet or injectable form. However, for better patient adherence, especially in pediatric or non-compliant populations, novel drug delivery systems like isoniazid gummies have been explored. Isoniazid gummies offer a palatable, easy-to-administer alternative to the conventional oral tablets, potentially improving compliance in both children and adults undergoing TB treatment or prophylaxis. This formulation combines isoniazid with excipients designed to create a stable, bioavailable, and flavourful product that can be taken conveniently. The development process focuses on optimizing the release and absorption of isoniazid while ensuring that the therapeutic efficacy remains unchanged. This dosage form may address challenges associated with traditional medication intake, Studies on isoniazid gummies will need to evaluate their pharmacokinetics, safety profile, and overall therapeutic efficacy compared to conventional isoniazid formulations. Such innovations aim to enhance patient comfort and treatment outcomes, contributing to the broader goal of TB control worldwide. The first solution contained sorbitol, sucrose, and water 1:1, with a water-to-sorbitol ratio of 2:1. In order to make the second solution, water and gelatin were mixed and heated at 60°C. Both solutions were mixed, followed by the addition of other excipients. Preformulating studies involved bulk characterization and solubility analysis. Solubility analysis (pKa determination and partition coefficient) was carried out. Post-formulation studies were carried out to characterize the formulation, including in vitro disintegration and dissolution. A release kinetics study of the formulation revealed that these gummies followed first-order kinetics because it is an immediate-release formulation.